Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28062471 | 0.97 | GAA (0.48) | GAAKDM4ELMNAHTTALDH1A1 | |
| SCHEMBL21650382 | 0.80 | GAA (0.43) | GAAKDM4ELMNAHTTALDH1A1 | |
| SCHEMBL6917528 | 0.77 | GAA (0.48) | GAAKDM4ELMNAHTTALDH1A1 | |
| SCHEMBL19313228 | 0.75 | PKM (0.44) | GAAKDM4EHTTTSHRSMN1; SMN2 | |
| SCHEMBL27708554 | 0.75 | SMN1; SMN2 (0.40) | GAAKDM4ELMNAHTTALDH1A1 | |
| SCHEMBL6495036 | 0.73 | GAA (0.46) | GAAKDM4ELMNAHTTALDH1A1 | |
| SCHEMBL19766578 | 0.73 | GAA (0.42) | GAAKDM4ELMNAHTTALDH1A1 | |
| SCHEMBL18884498 | 0.72 | NMT1 (0.33) | GAAKDM4EHTTNMT1SMN1; SMN2 | |
| SCHEMBL18903854 | 0.72 | GAA (0.44) | GAAKDM4ELMNAHTTALDH1A1 | |
| SCHEMBL18904130 | 0.72 | GAA (0.44) | GAAKDM4ELMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-113735916-B | Method for converting terminal alkyne into amide and application of method in construction of gene coding library | 康龙化成(宁波)科技发展有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-115806550-A | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-109641886-B | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-111285806-B | Pyrazole compound and preparation method, application and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2022-04-15 | — | — | CN | disclosed |
| CN-113735916-A | Method for converting terminal alkyne into amide and application of method in construction of gene coding library | 康龙化成(宁波)科技发展有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-111285806-A | Pyrazole compound and preparation method, application and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2020-06-16 | — | — | CN | disclosed |
| WO-2018132547-A1 | REVERSAL OF FOSFOMYCIN RESISTANCE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-07-19 | — | — | WO | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| WO-2014084330-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 協和発酵キリン株式会社 (JP) | 2014-06-05 | — | — | WO | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| WO-2010010188-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | GAA 358/4885KDM4E 3676/4885LMNA 3544/4885 |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | GAA 3304/4885KDM4E 2643/4885LMNA 4876/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | GAA 358/4885KDM4E 3676/4885LMNA 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.